Iron oxide nanoparticles suppress the production of IL-1beta via the secretory lysosomal pathway in murine microglial cells
© Wu et al.; licensee BioMed Central Ltd. 2013
Received: 15 April 2013
Accepted: 9 September 2013
Published: 18 September 2013
Superparamagnetic iron oxide nanoparticles (IONPs) have been used as magnetic resonance imaging contrast agents for various research and diagnostic purposes, such as the detection of neuroinflammation and blood-brain-barrier integrity. As the central resident macrophage-like cells, microglia are responsible for managing foreign agents invading the CNS. The present study investigated the direct effect of IONPs on the production of pro-inflammatory cytokines by murine microglia stimulated with lipopolysaccharide (LPS).
Primary murine microglial cells were pretreated with IONPs (1–50 μg Fe/mL) for 30 min and then stimulated with LPS (100 ng/mL) for 24 h. Confocal microscopy is used to visualize the intracellular IONP distribution and secretory lysosomes after staining with LysoTracker and Rab27a, respectively. The production of interleukin (IL)-1β and tumor necrosis factor (TNF)-α was quantified by ELISA. The activity of IL-1β converting enzyme (ICE) and TNF-α converting enzyme (TACE) was measured by fluorescent microplate assay using specific substrates. The lysosomal number, alkalinity, permeability and cathepsin B activity were determined by flow cytometry with ectodermal dysplasia-1, lysosensor and acridine orange staining, and using cathepsin B specific substrate, respectively.
Confocal imaging revealed that IONPs were markedly engulfed by microglia. Exposure to IONPs attenuated the production of IL-1β, but not TNF-α. Concordantly, the activity of ICE, but not the TACE, was suppressed in IONP-treated cells. Mechanistic studies showed that IONPs accumulated in lysosomes and the number of lysosomes was increased in IONP-treated cells. In addition, exposure to IONPs increased lysosomal permeability and alkalinity, but decreased the activity of cathepsin B, a secretory lysosomal enzyme involved in the activation of ICE.
Our results demonstrated a contrasting effect of IONPs on the production of IL-1β and TNF-α by LPS-stimulated microglia, in which the attenuation of IL-1β by IONPs was mediated by inhibiting the secretory lysosomal pathway of cytokine processing.
KeywordsCathepsin B Interleukin-1β Iron oxide nanoparticle Lipopolysaccharide Microglia Secretory lysosome
Iron oxide nanoparticles (IONPs) have been employed for a variety of biomedical research and diagnostic purposes, including cancer treatment, cell labeling, drug delivery and magnetic resonance imaging (MRI) [1–4]. Previous studies reported that IONPs affected the viability and functionality of macrophages, including the induction of oxidative stress and apoptosis, and the suppression of phagocytic activity and cytokine production [5–9]. In addition, IONPs have been shown capable of crossing the blood-brain-barrier, rendering IONPs a promising imaging agent for the diagnosis of neuroinflammation and brain injury [10–12]. In light of the increasingly applications of IONPs for the diagnostic imaging of the central nervous system (CNS), the interaction between brain cells and IONPs is a relevant issue to be addressed. To date, it remains mostly elusive if IONPs influence the functionality of central immune cells, such as microglia.
Microglia are the brain-resident macrophage-like immunocompetent cells responsible for the surveillance of homeostasis in the CNS. In response to pathogen infection, foreign agent invasion and injury, microglia are rapidly activated, and undergo morphologic and functional alterations, including proliferation, migration to the site of inflammation, and phagocytosis of foreign agents and cell debris. In addition, activated microglia produce pro-inflammatory cytokines and cytotoxic factors, including interleukin (IL)-1β, nitric oxide (NO), tumor necrosis factor (TNF)-α and reactive oxygen species (ROS) [13, 14]. These mediators play a key role in the prevention of brain cells from further damage and to promote the repair of the damaged tissue. For example, IL-1β produced by activated microglia enhances the proliferation of astrocytes, stimulates neovascularization and promotes the repair of nervous tissues [15–18]. Microglial TNF-α can promote neural cell survival and proliferation, and enhance the release of glutamate from astrocytes [19, 20]. Previous studies reported that intranasal administration of gold nanoparticles to mice induced microglial activation and internalization of gold nanoparticles, and a transient up-regulation of Toll-like receptor-2 in the olfactory bulb . In addition, intranasal exposure of mice to IONPs resulted in the transportation of the nanoparticles into the brain via the olfactory route, and induced the recruitment, activation and proliferation of microglia cells in the brain. Exposure of BV2 microglial cells to IONPs elicited a marked production of ROS and NO. IONPs were also found to be engulfed by BV2 cells, which induced a large number of cellular vesicles, swelling of endoplasmic reticulum and morphological alterations of mitochondrial cristae . Collectively, these results indicate that the functionality and morphology of resting microglia are altered in response to nanoparticle exposure. Microglia play a pivotal role in neuroinflammation, in which they can be activated by various stimuli, such as lipopolysaccharides (LPS) derived from Gram-negative bacteria. To date, evidence pertaining to the potential impact of IONPs on the functionality of activated microglia is scarce. The objective of the present study was to investigate the effect of IONPs on the expression of pro-inflammatory cytokines by LPS-activated microglia. Here, we reported that IONPs suppressed the production of IL-1β by activated microglia via the secretory lysosomal pathway of cytokine processing.
Results and discussion
Characterization of IONPs and uptake of IONPs by primary microglia
IONPs did not affect the viability of primary microglia
Although IONPs are generally considered biocompatible, high concentrations of IONPs have been reported to cause cytotoxicity in several glial lines . Moreover, IONPs induced the disappearance of mitochondrial cristae and swelling of endoplasmic reticulum (ER) in BV2 microglial cells . Five-day exposure to IONPs elicited ROS-mediated apoptosis in human macrophages . Other metal nanoparticles such as titanium dioxide also induced apoptosis in murine N9 microglial cells . It is currently unclear whether IONPs affect the viability of primary microglia. Hence, the cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. Exposure to IONPs (1–50 μg Fe/mL) for 24 h did not affect cell viability compared to the LPS-stimulated control group (Figure 1B), and the morphology of cells appeared unchanged (Figure 1A). These results are in line with previous results showing that a 24-h exposure of macrophages to carboxydextran-coated IONPs induced no cytotoxicity [6, 9, 29].
IONPs differentially modulated the production of proinflammatory cytokines by LPS-stimulated microglia
Cytokines can be processed via the classical or nonclassical secretory pathway. In particular, TNF-α is released through the classical pathway, in which newly synthesized pro-TNF-α was trafficked from the ER through the Golgi to recycling endosomes, which fused with cell membrane for the cleavage of pro-TNF-α by TACE and then exocytotic release of mature TNF-α [32, 33]. In contrast to the processing of TNF-α, IL-1β lacks the N-terminal signal sequence required for ER entry and thus is released through the non-classical pathway independent of ER/Golgi trafficking . Several mechanisms associated with the release of IL-1β have been proposed, including the exocytosis of IL-1β containing secretory lysosomes, shedding of plasma membrane microvesicles, release of IL-1β exosomes from multivesicular bodies and export of IL-1β through ATP-binding cassette transporters [35, 36]. Previous studies showed that silica-based nanoparticles inhibited the mRNA expression of TNF-α by microglia . Interestingly, our data revealed that exposure of LPS-stimulated microglia to IONPs inhibited ICE activity and IL-1β secretion, whereas TACE and TNF-α were unaltered (Figure 2), indicating that the non-classical secretory pathway, rather than the ER/Golgi classical secretory pathway, was affected by IONPs.
IONPs located in lysosomes and increased the number of lysosomes
IONPs attenuated the activity of cathepsin B
IONPs elevated lysosomal alkalinity and permeability
IL-1β is one of the major pro-inflammatory cytokine produced by activated microglia, which induces the production of IL-6 and NO in astrocytes [16, 17], and increase oxidative activity in microglia . In addition, IL-1β released by microglia induces the proliferation of astrocytes, stimulates neovascularization and promotes repair of the CNS in brain injury [15, 18]. In the present study, we showed that IONPs attenuated IL-1β production by suppressing the secretory lysosomal functionality in LPS-stimulated microglia. These results suggest that IONPs might impair the host defense against pathogens and the repairing capacity in the CNS. In addition, microglia are the major immunocompetent cells possessing antigen-presenting functions in the CNS . It has been shown that lysosomal cysteine proteases, including cathepsin B, are involved in the regulation of antigen processing in APC . Our data showing the suppression of cathepsin B activity by IONPs suggest that the microglial capability of antigen processing may also be affected. Further studies are warranted to address this issue.
The present study showed that IONPs accumulated in lysosomes and suppressed the production of IL-1β by affecting the secretory lysosomal pathway of cytokine processing in LPS-stimulated microglia. These findings provide new insights to the potential impact of IONP exposure on the functionality of activated microglia and indicate lysosomes as a crucial intracellular target for IONPs. Together with previous reports showing various effects on microglial functionality by other nanoparticles, including gold, silica, and titanium oxide [21, 37, 49, 52], exposure to nanoparticles may cause microglial dysfunction leading to deleterious influence on the central immune homeostasis.
All reagents were purchased from Sigma Chemical (St Louis, MO) unless otherwise stated. Resovist®, a commercial preparation of carboxydextran-coated iron oxide nanoparticles (IONPs) containing 28 mg Fe/mL, was obtained from Schering AG (Berlin, Germany). Dulbecco’s Modified Eagle Medium (DMEM) was obtained from Caisson Laboratories (Rexburg, ID). Fetal bovine serum (FBS), horse serum (HS) and cell culture reagents were purchased from GIBCO BRL (Gaithersburg, MD). Enzyme-linked immunosorbent assay (ELISA) sets for cytokine measurement were purchased from BD Biosciences (San Diego, CA). ICE/Caspase 1 protease assay kit and fluorogenic substrates Ac-YVAD-AFC (7-amino-4-methylcoumarin) were obtained from Chemicon (Temecula, CA) and Tocris (Bristol, UK), respectively. TACE fluorogenic activity assay kit was purchased from AnaSpec (San Jose, CA). Magic Red™ cathepsin B detection kit was purchased from Immunochemistry Technologies (Bloomington, MN).
Culture of primary murine microglial cells
Primary mix glial cultures were prepared as previously described with minor modifications . Briefly, after decapitation, forebrains of new-born BALB/c mice were dissociated mechanically. Their meninges were removed aseptically and the brain cells were resuspended in DMEM containing 10% FBS, 10% HS, 4 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. The cells were cultured on poly-D-lysine (25 μg/mL)-coated flasks, and medium was replenished 6–8 days after initial seeding. Upon reaching confluence (12−16 days), loosely adherent microglial cells were collected by shaking at 165 rpm at 37°C for 3 h. The enriched microglial cells were cultured on culture plates for 2 h to allow attachment, and then the medium was changed to DMEM containing 1% HS, 4 mM L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin for experiments with IONPs exposure. In all cases, the cells were cultured at 37°C in 5% CO2. The purity of microglial culture was > 90% as determined by flow cytometry with CD11b staining.
Characterization of IONPs
The particle size distribution and zeta potential of the IONPs were measured by phase analysis light scattering using Zetasizer nano-ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK). IONPs were appropriately diluted with 0.22 μm-filtered saline for size measurement at 25°C. The zeta potentials of IONPs in saline and culture medium (DMEM containing 1% horse serum) were measured at 25°C.
Confocal imaging of engulfed nanoparticles and lysosomes
Microglial cells (4 × 105 cells/mL) cultured on cover slips were pretreated with IONPs (1–50 μg Fe/mL) for 30 min followed by stimulation with LPS (100 ng/mL; Escherichia coli O55:B5) for 24 h. The cells were stained with 1 μM LysoTracker™ Red DND-99 (Invitrogen, Carlsbad, CA) for 2 h at 37°C. After washing, the cells were fixed with 4% paraformaldehyde for 15 min at room temperature. For detection of nuclei, the fixed cells were stained with Hoechst 33258 (5 μg/mL) at room temperature for 5 min. After washing, the cells were mounted in ProLong Gold antifade reagent (Invitrogen, Carlsbad, CA) and visualized on a Leica TCS SP5 II scanning confocal microscope (Leica Microsystems, Wetzlar, Germany).
Measurement of cell viability
The viability of microglia was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. Microglial cells (4 × 105 cells/mL) were cultured in quadruplicate in a 96-well plate (0.1 mL/well). The cells were either left untreated (naïve; NA), or pretreated with IONPs (1–50 μg Fe/mL) for 30 min followed by stimulation with LPS (100 ng/mL) for 24 h. An MTT stock solution (5 mg/mL) was added to each well (10 μL/well) 4 h before the end of incubation. After washing, the formed formazan was dissolved by the addition of lysis buffer (10% SDS in N,N-dimethylformamide; 200 μL/well). The absorbance of the formazan product was measured at 570 nm and at 630 nm as a background reference, using a microplate reader (Dynatech Laboratories, Chantilly, VA).
Measurement of cytokines
Microglial cells (4 × 105 cells/mL) were cultured in tripricate in a 48-well plate (0.25 mL/well) and treated with IONPs and LPS as described above in the MTT assay. The supernatants were collected and quantified for IL-1β and TNF-α by standard sandwich ELISA.
Measurement of ICE and TACE activity
Microglial cells (4 × 105 cells/mL) were cultured in a 6-cm dish (5.5 mL/dish) and treated with IONPs and LPS as described above in the MTT assay. After washing, the cells were harvested and lysed with cell lysis buffer. The lysates were incubated with 200 μM of the ICE fluorogenic substrates Ac-YVAD-AFC and 5 mM of DTT for 1 h at 37°C, and the fluorescence was measured at 400 nm excitation and 505 nm emissions. The cell lysates were also incubated with 40 μM of the TACE fluorogenic substrate for 1 h at 37°C in the dark with gentle shaking, and the fluorescence was detected at 490 nm excitation and 520 nm emissions.
Analysis of the amount of lysosomes
Microglial cells (4 × 105 cells/mL) were cultured in tripricate in a 24-well plate (0.5 mL/well) and treated with IONPs and LPS as described above in the MTT assay. The cells were fixed in 4% paraformaldehyde, permeabilized with 0.2% Trion-X and incubated in blocking buffer containing 2.5% BSA in PBS for 30 min at 4°C. The cells were then stained with appropriately diluted APC-labeled rat anti-mouse ED-1 antibody (BioLegend, CA) for 1 h at 4°C in the dark. After washing, the fluorescence of 5000 single cells for each sample was measured using a flow cytometer at emission of 670 nm (BD LSRFortessa, San Jose, CA). The data were analyzed using the software Flowjo 5.7.
Measurement of lysosomal acidity and permeability
The acidity and permeability of lysosome were determined by flow cytometry using LysoSensor™ Green DND-189 and acridine orange, respectively. Microglial cells (4 × 105 cells/mL) were cultured in tripricate in a 48-well plate (0.25 mL/well) and treated with IONPs and LPS as described above in the MTT saasy. The cells were stained with 1 μM Lysosensor™ for 2 h or 5 μg/mL acridine orange for 10 min at 37°C. After washing, the fluorescence of 5000 single cells for each sample was measured using a flow cytometer at emission of 525 nm and 610 nm for Lysosensor™ and acridine orange, respectively.
Detection of cathepsin B enzyme activity and secretory lysosomes
Microglial cells (4 × 105 cells/mL) were cultured in tripricate in a 48-well plate (0.25 mL/well) and treated with IONPs and LPS as described above in the MTT assay. The cells were stained with Magic Red™ cathepsin B substrate for 1 h at 37°C. Once the substrate is cleaved by active cathepsin B, its product emits red fluorescence whose intensity is a direct measurement of the enzymatic activity of cathepsin B. After washing, the fluorescence of 5000 single cells for each sample was measured using a flow cytometer at emission of 610 nm and visualized on a Leica TCS SP5 II scanning confocal microscope. The secretory lysosomes in microglia were stained with appropriately diluted Alexa Fluor 488-labeled rabbit anti-Rab27a antibody (Bioss, MA) and visualized by confocal microscopy as described above for ED-1 staining.
The mean ± standard error (SE) was determined for each treatment group in the individual experiments. Homogeneous data were evaluated by a parametric analysis of variance, and Dunnett’s two-tailed t- test was used to compare treatment groups to the control group. P value < 0.05 was defined as statistical significance.
Central nervous system
Dulbecco’s Modified Eagle Medium
Enzyme-linked immunosorbent assay
Fetal bovine serum
IL-1β converting enzyme
Iron oxide nanoparticles
Mean fluorescence intensity
Magnetic resonance imaging
Reactive oxygen species
TNF-α converting enzyme
Tumor necrosis factor.
This work was supported in part by grants NSC101-2321-B-002-053 and NSC102-2321-B002-040 from the National Science Council, Executive Yuan, Taiwan.
- Xie J, Huang J, Li X, Sun S, Chen X: Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 2009, 16: 1278–1294. 10.2174/092986709787846604View ArticlePubMedGoogle Scholar
- Yu MK, Jeong YY, Park J, Park S, Kim JW, Min JJ, Kim K, Jon S: Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl 2008, 47: 5362–5365. 10.1002/anie.200800857View ArticlePubMedGoogle Scholar
- Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI: Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008, 2: 889–896. 10.1021/nn800072tPubMed CentralView ArticlePubMedGoogle Scholar
- Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P: Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul 1996, 13: 245–255. 10.3109/02652049609026013View ArticlePubMedGoogle Scholar
- Shen CC, Wang CC, Liao MH, Jan TR: A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int J Nanomedicine 2011, 6: 1229–1235.PubMed CentralPubMedGoogle Scholar
- Lunov O, Syrovets T, Buchele B, Jiang X, Rocker C, Tron K, Nienhaus GU, Walther P, Mailander V, Landfester K, Simmet T: The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. Biomaterials 2010, 31: 5063–5071. 10.1016/j.biomaterials.2010.03.023View ArticlePubMedGoogle Scholar
- Chen BA, Jin N, Wang J, Ding J, Gao C, Cheng J, Xia G, Gao F, Zhou Y, Chen Y, et al.: The effect of magnetic nanoparticles of Fe(3)O(4) on immune function in normal ICR mice. Int J Nanomedicine 2010, 5: 593–599.PubMed CentralView ArticlePubMedGoogle Scholar
- Cho WS, Cho M, Kim SR, Choi M, Lee JY, Han BS, Park SN, Yu MK, Jon S, Jeong J: Pulmonary toxicity and kinetic study of Cy5.5-conjugated superparamagnetic iron oxide nanoparticles by optical imaging. Toxicol Appl Pharmacol 2009, 239: 106–115. 10.1016/j.taap.2009.05.026View ArticlePubMedGoogle Scholar
- Hsiao JK, Chu HH, Wang YH, Lai CW, Chou PT, Hsieh ST, Wang JL, Liu HM: Macrophage physiological function after superparamagnetic iron oxide labeling. NMR Biomed 2008, 21: 820–829. 10.1002/nbm.1260View ArticlePubMedGoogle Scholar
- Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, Muldoon LL, Neuwelt EA: Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010, 30: 15–35. 10.1038/jcbfm.2009.192PubMed CentralView ArticlePubMedGoogle Scholar
- Thorek DL, Weisshaar CL, Czupryna JC, Winkelstein BA, Tsourkas A: Superparamagnetic iron oxide-enhanced magnetic resonance imaging of neuroinflammation in a rat model of radicular pain. Mol Imaging 2011, 10: 206–214.PubMedGoogle Scholar
- Jin AY, Tuor UI, Rushforth D, Filfil R, Kaur J, Ni F, Tomanek B, Barber PA: Magnetic resonance molecular imaging of post-stroke neuroinflammation with a P-selectin targeted iron oxide nanoparticle. Contrast Media Mol Imaging 2009, 4: 305–311. 10.1002/cmmi.292View ArticlePubMedGoogle Scholar
- Aloisi F: Immune function of microglia. Glia 2001, 36: 165–179. 10.1002/glia.1106View ArticlePubMedGoogle Scholar
- Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19: 312–318. 10.1016/0166-2236(96)10049-7View ArticlePubMedGoogle Scholar
- Giulian D, Lachman LB: Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 1985, 228: 497–499. 10.1126/science.3872478View ArticlePubMedGoogle Scholar
- Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995, 20: 269–287. 10.1016/0165-0173(94)00015-HView ArticlePubMedGoogle Scholar
- Lee SC, Dickson DW, Brosnan CF: Interleukin-1, nitric oxide and reactive astrocytes. Brain Behav Immun 1995, 9: 345–354. 10.1006/brbi.1995.1032View ArticlePubMedGoogle Scholar
- Mason JL, Suzuki K, Chaplin DD, Matsushima GK: Interleukin-1beta promotes repair of the CNS. J Neurosci 2001, 21: 7046–7052.PubMedGoogle Scholar
- Smith JA, Das A, Ray SK, Banik NL: Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012, 87: 10–20. 10.1016/j.brainresbull.2011.10.004View ArticlePubMedGoogle Scholar
- Hanisch UK: Microglia as a source and target of cytokines. Glia 2002, 40: 140–155. 10.1002/glia.10161View ArticlePubMedGoogle Scholar
- Hutter E, Boridy S, Labrecque S, Lalancette-Hebert M, Kriz J, Winnik FM, Maysinger D: Microglial response to gold nanoparticles. ACS Nano 2010, 4: 2595–2606. 10.1021/nn901869fView ArticlePubMedGoogle Scholar
- Wang Y, Wang B, Zhu MT, Li M, Wang HJ, Wang M, Ouyang H, Chai ZF, Feng WY, Zhao YL: Microglial activation, recruitment and phagocytosis as linked phenomena in ferric oxide nanoparticle exposure. Toxicol Lett 2011, 205: 26–37. 10.1016/j.toxlet.2011.05.001View ArticlePubMedGoogle Scholar
- Shen CC, Liang HJ, Wang CC, Liao MH TRJ: A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. Int J Nanomedicine 2011, 6: 2791–2798.PubMed CentralPubMedGoogle Scholar
- Mou Y, Chen B, Zhang Y, Hou Y, Xie H, Xia G, Tang M, Huang X, Ni Y, Hu Q: Influence of synthetic superparamagnetic iron oxide on dendritic cells. Int J Nanomedicine 2011, 6: 1779–1786.PubMed CentralPubMedGoogle Scholar
- Yang CY, Tai MF, Lin CP, Lu CW, Wang JL, Hsiao JK, Liu HM: Mechanism of cellular uptake and impact of ferucarbotran on macrophage physiology. PloS one 2011, 6: e25524. 10.1371/journal.pone.0025524PubMed CentralView ArticlePubMedGoogle Scholar
- Yeh CH, Hsiao JK, Wang JL, Sheu F: Immunological impact of magnetic nanoparticles (Ferucarbotran) on murine peritoneal macrophages. J Nanoparticle Res : Interdiscip Forum Nanoscale Sci Technol 2010, 12: 151–160.View ArticleGoogle Scholar
- Ankamwar B, Lai TC, Huang JH, Liu RS, Hsiao M, Chen CH, Hwu YK: Biocompatibility of Fe(3)O(4) nanoparticles evaluated by in vitro cytotoxicity assays using normal, glia and breast cancer cells. Nanotechnol 2010, 21: 75102. 10.1088/0957-4484/21/7/075102View ArticleGoogle Scholar
- Li X, Xu S, Zhang Z, Schluesener H: Apoptosis induced by titanium dioxide nanoparticles in cultured murine microglia N9 cells. Chin Sci Bull 2009, 54: 3830–3836. 10.1007/s11434-009-0548-xView ArticleGoogle Scholar
- Yeh C-H, Hsiao J-K, Wang J-L, Sheu F: Immunological impact of magnetic nanoparticles (Ferucarbotran) on murine peritoneal macrophages. J Nanopart Res 2010, 12: 151–160. 10.1007/s11051-009-9589-yView ArticleGoogle Scholar
- Chauvet N, Palin K, Verrier D, Poole S, Dantzer R, Lestage J: Rat microglial cells secrete predominantly the precursor of interleukin-1beta in response to lipopolysaccharide. Eur J Neurosci 2001, 14: 609–617. 10.1046/j.0953-816x.2001.01686.xView ArticlePubMedGoogle Scholar
- Black RA: Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002, 34: 1–5. 10.1016/S1357-2725(01)00097-8View ArticlePubMedGoogle Scholar
- Stow JL, Low PC, Offenhauser C, Sangermani D: Cytokine secretion in macrophages and other cells: pathways and mediators. Immunobiol 2009, 214: 601–612. 10.1016/j.imbio.2008.11.005View ArticleGoogle Scholar
- Lacy P, Stow JL: Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 2011, 118: 9–18. 10.1182/blood-2010-08-265892View ArticlePubMedGoogle Scholar
- Nickel W: The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem 2003, 270: 2109–2119. 10.1046/j.1432-1033.2003.03577.xView ArticlePubMedGoogle Scholar
- Nickel W, Rabouille C: Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009, 10: 148–155. 10.1038/nrm2617View ArticlePubMedGoogle Scholar
- Eder C: Mechanisms of interleukin-1beta release. Immunobiol 2009, 214: 543–553. 10.1016/j.imbio.2008.11.007View ArticleGoogle Scholar
- Choi J, Zheng Q, Katz HE, Guilarte TR: Silica-based nanoparticle uptake and cellular response by primary microglia. Environ Health Perspect 2010, 118: 589–595.PubMed CentralView ArticlePubMedGoogle Scholar
- Lunov O, Syrovets T, Rocker C, Tron K, Nienhaus GU, Rasche V, Mailander V, Landfester K, Simmet T: Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 2010, 31: 9015–9022. 10.1016/j.biomaterials.2010.08.003View ArticlePubMedGoogle Scholar
- Terada K, Yamada J, Hayashi Y, Wu Z, Uchiyama Y, Peters C, Nakanishi H: Involvement of cathepsin B in the processing and secretion of interleukin-1beta in chromogranin A-stimulated microglia. Glia 2010, 58: 114–124. 10.1002/glia.20906View ArticlePubMedGoogle Scholar
- Lunov O, Zablotskii V, Syrovets T, Rocker C, Tron K, Nienhaus GU, Simmet T: Modeling receptor-mediated endocytosis of polymer-functionalized iron oxide nanoparticles by human macrophages. Biomaterials 2011, 32: 547–555. 10.1016/j.biomaterials.2010.08.111View ArticlePubMedGoogle Scholar
- Luther EM, Petters C, Bulcke F, Kaltz A, Thiel K, Bickmeyer U, Dringen R: Endocytotic uptake of iron oxide nanoparticles by cultured brain microglial cells. Acta biomaterialia 2013, 9: 8454–8465. 10.1016/j.actbio.2013.05.022View ArticlePubMedGoogle Scholar
- Blott EJ, Griffiths GM: Secretory lysosomes. Nat Rev Mol Cell Biol 2002, 3: 122–131. 10.1038/nrm732View ArticlePubMedGoogle Scholar
- Griffiths G: What’s special about secretory lysosomes? Semin Cell Dev Biol 2002, 13: 279–284. 10.1016/S1084-9521(02)00057-5View ArticlePubMedGoogle Scholar
- Elstak ED, Neeft M, Nehme NT, Voortman J, Cheung M, Goodarzifard M, Gerritsen HC, van Bergen En Henegouwen PM, Callebaut I, de Saint Basile G, van der Sluijs P: The munc13–4-rab27 complex is specifically required for tethering secretory lysosomes at the plasma membrane. Blood 2011, 118: 1570–1578. 10.1182/blood-2011-02-339523View ArticlePubMedGoogle Scholar
- Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010, 12: 19–30. sup pp 11–13 10.1038/ncb2000View ArticlePubMedGoogle Scholar
- Guha S, Padh H: Cathepsins: fundamental effectors of endolysosomal proteolysis. Indian J Biochem Biophys 2008, 45: 75–90.PubMedGoogle Scholar
- Mort JS, Buttle DJ: Cathepsin B. Int J Biochem Cell Biol 1997, 29: 715–720. 10.1016/S1357-2725(96)00152-5View ArticlePubMedGoogle Scholar
- Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I: Activation of lysosomal function during dendritic cell maturation. Science 2003, 299: 1400–1403. 10.1126/science.1080106View ArticlePubMedGoogle Scholar
- Ma X, Wu Y, Jin S, Tian Y, Zhang X, Zhao Y, Yu L, Liang XJ: Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano 2011, 5: 8629–8639. 10.1021/nn202155yView ArticlePubMedGoogle Scholar
- Smith ME, van der Maesen K, Somera FP: Macrophage and microglial responses to cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production. J Neurosci Res 1998, 54: 68–78. 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-FView ArticlePubMedGoogle Scholar
- Honey K, Rudensky AY: Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 2003, 3: 472–482. 10.1038/nri1110View ArticlePubMedGoogle Scholar
- Long TC, Tajuba J, Sama P, Saleh N, Swartz C, Parker J, Hester S, Lowry GV, Veronesi B: Nanosize titanium dioxide stimulates reactive oxygen species in brain microglia and damages neurons in vitro. Environ Health Perspect 2007, 115: 1631–1637. 10.1289/ehp.10216PubMed CentralView ArticlePubMedGoogle Scholar
- Correa F, Docagne F, Mestre L, Clemente D, Hernangomez M, Loria F, Guaza C: A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol 2009, 77: 86–100. 10.1016/j.bcp.2008.09.014View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.